相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries
V. Corbo et al.
ANNALS OF ONCOLOGY (2012)
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2012)
Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms
Kathrin Zitzmann et al.
ENDOCRINE-RELATED CANCER (2012)
PI3K signalling: the path to discovery and understanding
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Limitations in Small Intestinal Neuroendocrine Tumor Therapy by mTor Kinase Inhibition Reflect Growth Factor-Mediated PI3K Feedback Loop Activation via ERK1/2 and AKT
Bernhard Svejda et al.
CANCER (2011)
Activating mutations of TOR (target of rapamycin)
Molly Hardt et al.
GENES TO CELLS (2011)
Loss of PTEN Expression in Neuroendocrine Pancreatic Tumors
M. Krausch et al.
HORMONE AND METABOLIC RESEARCH (2011)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Marianne E. Pavel et al.
LANCET (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
Compensatory activation of Akt in response to mTOR and Raf inhibitors - A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease
Kathrin Zitzmann et al.
CANCER LETTERS (2010)
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids
Maria Chiara Zatelli et al.
ENDOCRINE-RELATED CANCER (2010)
Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
Kathryn G. Foster et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway
Edoardo Missiaglia et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type
Stefano Barbi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Phosphatidylinositol 3-Kinase-Akt Signaling in Pulmonary Carcinoid Cells
Susan C. Pitt et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
New Insights into mTOR Signaling: mTORC2 and Beyond
Dario R. Alessi et al.
SCIENCE SIGNALING (2009)
The Pharmacology of mTOR Inhibition
David A. Guertin et al.
SCIENCE SIGNALING (2009)
Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line
Simona Grozinsky-Glasberg et al.
NEUROENDOCRINOLOGY (2008)
AKT1E17K in human solid tumours
F. E. Bleeker et al.
ONCOGENE (2008)
The PTEN-PI3K pathway: of feedbacks and cross-talks
A. Carracedo et al.
ONCOGENE (2008)
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer
Fanyin Meng et al.
GASTROENTEROLOGY (2007)
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells
Kathrin Zitzmann et al.
NEUROENDOCRINOLOGY (2007)
MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior
Claudia Roldo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Epidermal growth factor receptor expression and activation in neuroendocrine tumours
T Shah et al.
JOURNAL OF NEUROENDOCRINOLOGY (2006)
Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase
S Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
GV Thomas et al.
NATURE MEDICINE (2006)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
The NF1 tumor suppressor critically regulates TSC2 and mTOR
CM Johannessen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Chromosomal alterations detected by comparative genomic hybridization in nonfunctioning endocrine pancreatic tumors
G Floridia et al.
CANCER GENETICS AND CYTOGENETICS (2005)
Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies
OJ Shah et al.
CURRENT BIOLOGY (2004)
The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins
LS Harrington et al.
JOURNAL OF CELL BIOLOGY (2004)
Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin
CC Hudson et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
分享论文
